Friday, March 20, 2026 6:26:02 AM
Time only exists as it disappears — and maybe HCWB is the same: a possible illusion, or a fleeting opportunity. But if even 1 in 10 chances is real, by the time that becomes clear, the moment will already be gone. If time only exists as it vanishes, so does opportunity — and when the downside is already realized, the only thing left to fear is missing the moment.
Extremely small float
3–6 million shares
Abnormal volume
hundreds of millions of shares traded
a perfect setup for a squeeze
Narrative setup
strong scientific paper
updated deck ready
discussions with Big Pharma
Wugen deadline approaching
Extremely small float
3–6 million shares
Abnormal volume
hundreds of millions of shares traded
a perfect setup for a squeeze
Narrative setup
strong scientific paper
updated deck ready
discussions with Big Pharma
Wugen deadline approaching
Recent HCWB News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/31/2026 09:12:29 PM
- HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results • GlobeNewswire Inc. • 03/31/2026 09:05:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 12:00:07 PM
- HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic • GlobeNewswire Inc. • 03/17/2026 11:50:00 AM
- HCW Biologics highlights positive findings for CAR-T therapy manufacturing • IH Market News • 03/16/2026 02:31:28 PM
- HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances • GlobeNewswire Inc. • 03/16/2026 12:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/13/2026 08:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 01:08:36 PM
- HCW Biologics Regains Compliance with All Continued Listing Rules for Nasdaq Per Nasdaq Determination Letter • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2026 09:43:57 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/19/2026 08:46:38 PM
- HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules • GlobeNewswire Inc. • 02/18/2026 02:50:56 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/17/2026 02:09:25 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/13/2026 09:04:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2026 01:38:42 PM
- HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune • GlobeNewswire Inc. • 02/13/2026 01:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/11/2026 10:27:05 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/30/2026 05:15:19 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/09/2026 09:49:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/31/2025 05:36:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:30:26 PM
- HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 11/19/2025 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/18/2025 12:30:26 PM
- HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease • GlobeNewswire Inc. • 11/18/2025 12:25:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:52:53 PM
